In yesterday’s Wall Street session, Vericel Corporation (NASDAQ:VCEL) shares traded at $30.48, down -0.29% from the previous session.
5 analysts cover Vericel Corporation (NASDAQ:VCEL), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $44.00 and a low of $31.00, we find $38.00. Given the previous closing price of $30.57, this indicates a potential upside of 24.3 percent. VCEL stock price is now 7.82% away from the 50-day moving average and 15.94% away from the 200-day moving average. The market capitalization of the company currently stands at $1.39B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The stock has received a hold rating from 2 analysts and a buy rating from 3. Brokers who have rated the stock have averaged $37.75 as their price target over the next twelve months.
, while ‘Stephens’ rates the stock as ‘Overweight’.
In other news, SIEGAL JONATHAN, Principal Accounting Officer sold 330 shares of the company’s stock on Feb 02. The stock was sold for $10,230 at an average price of $31.00. Upon completion of the transaction, the Principal Accounting Officer now directly owns 675 shares in the company, valued at $20574.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 10, President and CEO Colangelo Dominick sold 39,938 shares of the business’s stock. A total of $1,083,598 was realized by selling the stock at an average price of $27.13. This leaves the insider owning 157,066 shares of the company worth $4.79 million. Insiders disposed of 64,166 shares of company stock worth roughly $1.96 million over the past 1 year. A total of 0.77% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VCEL stock. A new stake in Vericel Corporation shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $11,372,000. SG AMERICAS SECURITIES, LLC invested $2,223,000 in shares of VCEL during the first quarter. In the first quarter, AMALGAMATED FINANCIAL CORP. acquired a new stake in Vericel Corporation valued at approximately $699,000. HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND acquired a new stake in VCEL for approximately $671,000. MARYLAND STATE RETIREMENT & PENSION SYSTEM purchased a new stake in VCEL valued at around $593,000 in the second quarter.
On Wednesday morning Vericel Corporation (NASDAQ: VCEL) stock kicked off with the opening price of $30.56. During the past 12 months, Vericel Corporation has had a low of $17.30 and a high of $41.24. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.00, and a quick ratio of 4.60. The fifty day moving average price for VCEL is $28.39 and a two-hundred day moving average price translates $26.30 for the stock.
The latest earnings results from Vericel Corporation (NASDAQ: VCEL) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.14, missing analysts’ expectations of -$0.1 by -0.04. This compares to $0.10 EPS in the same period last year. The net profit margin was -10.20% and return on equity was -9.30% for VCEL. The company reported revenue of $52.69 million for the quarter, compared to $47.59 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 10.72 percent. For the current quarter, analysts expect VCEL to generate $52.94M in revenue.
Vericel Corporation(VCEL) Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
